SEC Comment Letter 0000000000-24-012891 to XORTX Therapeutics Inc. (XRTX) (CIK 0001729214) (XRTX)
XORTX Therapeutics Inc. (XRTX) (CIK 0001729214)
Date: Nov. 20, 2024 · CIK: 0001729214 · Accession: 0000000000-24-012891
AI Filing Summary & Sentiment
File numbers found in text: 333-283275
Letter
November 20, 2024 Allen Davidoff President and Chief Executive Officer XORTX Therapeutics Inc. 3710–33rd Street NW Calgary, Alberta, Canada T2L 2M1 Re:XORTX Therapeutics Inc. Registration Statement on Form F-1 Filed November 15, 2024 File No. 333-283275 Dear Allen Davidoff: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Nicole A. Edmonds
Show Raw Text
November 20, 2024
Allen Davidoff
President and Chief Executive Officer
XORTX Therapeutics Inc.
3710–33rd Street NW
Calgary, Alberta, Canada T2L 2M1
Re:XORTX Therapeutics Inc.
Registration Statement on Form F-1
Filed November 15, 2024
File No. 333-283275
Dear Allen Davidoff:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Nicole A. Edmonds